Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

A highly conserved neutralizing epitope on group 2 influenza a viruses

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

related to degree

  • Bhabha, Gira Sorab, Ph.D. in Biology, Scripps Research 2006 - 2011
  • Ekiert, Damian, Ph.D. in Chemical Biology, Scripps Research 2006 - 2011

authors

  • Ekiert, Damian
  • Friesen, R. H. E.
  • Bhabha, Gira Sorab
  • Kwaks, T.
  • Jongeneelen, M.
  • Yu, W. L.
  • Ophorst, C.
  • Cox, F.
  • Korse, Hjwm
  • Brandenburg, B.
  • Vogels, R.
  • Brakenhoff, J. P. J.
  • Kompier, R.
  • Koldijk, M. H.
  • Cornelissen, Lahm
  • Poon, L. L. M.
  • Peiris, M.
  • Koudstaal, W.
  • Wilson, Ian
  • Goudsmit, J.

publication date

  • August 2011

journal

  • Science  Journal

abstract

  • Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of V(H)1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the V(H)1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.

subject areas

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antibody Specificity
  • Antigens, Viral
  • Binding Sites, Antibody
  • Conserved Sequence
  • Crystallography, X-Ray
  • Epitopes
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Humans
  • Influenza A Virus, H3N2 Subtype
  • Influenza A Virus, H7N7 Subtype
  • Influenza A virus
  • Influenza Vaccines
  • Influenza, Human
  • Mice
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation
  • Neutralization Tests
  • Orthomyxoviridae Infections
  • Protein Conformation
scroll to property group menus

Identity

PubMed Central ID

  • PMC3210727

International Standard Serial Number (ISSN)

  • 0036-8075

Digital Object Identifier (DOI)

  • 10.1126/science.1204839

PubMed ID

  • 21737702
scroll to property group menus

Additional Document Info

start page

  • 843

end page

  • 850

volume

  • 333

issue

  • 6044

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support